Fo­cused on PhI­II, BeiGene touts ear­ly PD-1 re­sults; Am­gen part­ners with Sim­cere on Chi­na biosim­i­lars work

→ Hus­tling as fast as it can, BeiGene $BGNE to­day of­fered an ear­ly look at ear­ly-stage da­ta for its PD-1 check­point part­nered with Cel­gene $CELG. The com­pa­ny says it got the ini­tial tu­mor re­spons­es it was look­ing for — with no dose-lim­it­ing tox­i­c­i­ty — as re­searchers pur­sue two reg­is­tra­tion stud­ies for BGB-A317 in urothe­lial can­cer and clas­si­cal Hodgkin lym­phoma. The Chi­na-based biotech has a slate of Phase III stud­ies in the pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.